Publication:

Common variants associated with plasma triglycerides and risk for coronary artery disease

Loading...
Thumbnail Image

Date

2013

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Do, R., C. J. Willer, E. M. Schmidt, S. Sengupta, C. Gao, G. M. Peloso, S. Gustafsson, et al. 2013. “Common variants associated with plasma triglycerides and risk for coronary artery disease.” Nature genetics 45 (11): 1345-1352. doi:10.1038/ng.2795. http://dx.doi.org/10.1038/ng.2795.

Abstract

Triglycerides are transported in plasma by specific triglyceride-rich lipoproteins; in epidemiologic studies, increased triglyceride levels correlate with higher risk for coronary artery disease (CAD). However, it is unclear whether this association reflects causal processes. We used 185 common variants recently mapped for plasma lipids (P<5×10−8 for each) to examine the role of triglycerides on risk for CAD. First, we highlight loci associated with both low-density lipoprotein cholesterol (LDL-C) and triglycerides, and show that the direction and magnitude of both are factors in determining CAD risk. Second, we consider loci with only a strong magnitude of association with triglycerides and show that these loci are also associated with CAD. Finally, in a model accounting for effects on LDL-C and/or high-density lipoprotein cholesterol, a polymorphism's strength of effect on triglycerides is correlated with the magnitude of its effect on CAD risk. These results suggest that triglyceride-rich lipoproteins causally influence risk for CAD.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories

Story
Common variants associated with plasma triglycerides… : DASH Story 2016-12-02
I am ex-Harvard Med School Faculty (1987–1994). Worked in pharmaceutical industry for 20 years. Now I work independently with investors to build new biotech companies. It is very difficult to attract funding and investment for early stage proof of concept studies, such as repurposing of old drugs for new clinical indications. Open access is the only way for me to access some of the scientific literature to understand scientific background for this work.